Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUROXAV: XAV-19 for moderate to severe COVID-19
2020-005979-12Phase 2Terminated
- Sponsor
- Xenothera
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing XAV-19 infusion with Placebo infusion (2 arms). Primary endpoint: Clinical aggravation within 8 days. Started Feb 2021; status: terminated.
02
Drugs
xav-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005979-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005979-12.